ad2/hif-1alpha/vp16
Gene therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00117650)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Hypoxia-inducible factor 1-alphaSupplementation
HIF1A supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad2/hif-1alpha/vp16
- ad2/hif-1α/vp16
- hif-1alpha
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00117650 | Phase 2 | Feb 1, 2005 | Genzyme |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1